Meloxicam Kleva 7,5 Mg

Meloxicam, the active ingredient in Meloxicam Kleva 7,5 Mg, is a NSAID presented as a 7.5 mg tablet for oral use. It treats osteoarthritis, rheumatoid arthritis and acute pain in adults.

GNH USA supplies Meloxicam Kleva 7,5 Mg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meloxicam is a non‑steroidal anti‑inflammatory drug used to manage inflammatory joint conditions and acute pain.

- Osteoarthritis: reduces joint pain and improves functional ability. - Rheumatoid arthritis: decreases inflammation and slows disease progression. - Acute pain: provides short‑term relief of moderate pain.

Adverse reactions may occur with meloxicam use.

Common Side Effects: - Gastro‑intestinal discomfort or dyspepsia. - Headache. - Dizziness. - Mild skin rash. - Elevated blood pressure. - Peripheral edema.

Serious or Rare Side Effects: - Gastro‑intestinal ulceration or bleeding. - Severe liver injury (hepatotoxicity). - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Acute renal impairment. - Cardiovascular thrombotic events (myocardial infarction, stroke). - Anaphylactic or severe hypersensitivity reactions.

Before prescribing meloxicam, clinicians should evaluate patient‑specific risk factors and monitor for adverse events.

- Renal function: assess baseline and monitor in patients with renal impairment. - Hepatic function: evaluate liver enzymes prior to initiation and during therapy. - Cardiovascular risk: use cautiously in patients with a history of heart disease or stroke. - Gastro‑intestinal safety: avoid in patients with active peptic ulcer disease or a history of serious GI bleeding. - Pregnancy and lactation: contraindicated unless benefits outweigh potential risks; consult obstetric guidance. - Store at room temperature below 25°C: keep in the original container, protect from moisture and light.

Meloxicam may interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Lithium: elevated lithium serum concentrations. - Methotrexate: enhanced toxicity, especially at high doses. - Cyclosporine: heightened nephrotoxic potential.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: possible decline in renal function. - Diuretics: risk of electrolyte imbalance and reduced renal clearance. - SSRIs or SNRIs: additive bleeding risk, monitor for signs of hemorrhage.